Key Points {#d30e199}
==========

Preliminary data from randomized controlled trials have demonstrated that ketamine may rapidly and effectively control treatment-resistant depression, though the effects are transient.A small subset of studies has demonstrated similar results in the effects of ketamine on suicidal ideation.Ketamine has potential as a rapid treatment for suicidal ideation and/or a possible model compound for future drug development.

Introduction {#Sec1}
============

For decades, ketamine has been recognized as an anesthetic by the medical and veterinary worlds. It has long been used as an anesthetic for children \[[@CR1]\] and is also occasionally used as an anesthetic for administration of electroconvulsive therapy (ECT) to patients with high seizure thresholds \[[@CR2]\]. Its use for medical indications is attributable to its safety and wide therapeutic range \[[@CR3]\]. Only recently has it been utilized for the treatment of depression and suicidal ideation (SI). First described by Berman et al. \[[@CR4]\], ketamine has since been observed in several small randomized controlled trials to rapidly reduce depressive symptoms and SI \[[@CR4]--[@CR11]\]. Several review papers and recommendations have been written regarding application of ketamine in treatment-resistant depression (TRD), as well as for depressive episodes of bipolar disorder, but few have directly addressed its usefulness for treating SI. Nonetheless, a recent post hoc analysis of four studies found that ketamine has an impact on SI that is independent of improvement in depression and anxiety \[[@CR12]\]. Therefore, the aim of the current review is to provide an overview of the data describing the clinical efficacy of ketamine in SI. There are no current studies that have examined ketamine for suicide attempts and suicidal behavior as outcomes.

Methods {#Sec2}
=======

The PubMed and Cochrane databases were searched by the two authors (L. R. and N. A. Y.) independently to select relevant studies published up to January 2015, using combinations of the terms "ketamine," "suicidal ideation," "suicide," "suicidal," and "suicidality." After all publications were obtained, the articles were individually reviewed and the following inclusion criteria were used for selection: the publication was in the English language; the patients had SI measured at baseline; and the publication was in a peer-reviewed journal. Because only a limited number of studies directly assessed SI, we included randomized controlled trials, open-label uncontrolled studies, and case series/reports. A total of 41 articles were reviewed, and nine met our inclusion criteria (Fig. [1](#Fig1){ref-type="fig"}). A combination of relevant reference citations within the original nine publications and additional searches for necessary background information completed the total data collection.Fig. 1Search strategy for the systematic review of ketamine as a treatment for suicidal ideation or suicidality

Results {#Sec3}
=======

A total of nine publications (six studies and three case reports) investigated the efficacy of ketamine for SI \[[@CR4], [@CR7], [@CR10], [@CR11], [@CR13]--[@CR17]\]. Three of these studies were randomized controlled trials \[[@CR4], [@CR11], [@CR18]\], three were open-label non-randomized studies \[[@CR15]--[@CR17]\], and three were case reports \[[@CR10], [@CR13], [@CR14]\]. Similar to the findings of studies examining patients with TRD, a reduction in SI was seen as early as 40 min and lasted for an average of 3 days. The results are summarized in Table [1](#Tab1){ref-type="table"} and are discussed further below.Table 1Studies and cases of ketamine as treatment for suicidal ideation (SI)ReferencesDesign, sample sizePatient selectionTreatmentOutcome measuresResultsBerman et al. \[[@CR4]\]RCT crossover, *n* = 8MDD0.5 mg/kg IV or placebo over 40 minHDRS items related to SISI symptoms decreased during ketamine treatment (*p* = 0.02)Price et al. \[[@CR16]\]Open study, *n* = 26TRD0.5 mg/kg IV over 40 minMADRS-SIAt 24 h, MADRS-SI scores were 0--1 (*n* = 8), 2--3 (*n* = 3), ≥4 (*n* = 2)Subset: MADRS-SI score ≥4 (*n* = 13)DiazGranados et al. \[[@CR17]\]Open study, *n* = 33MDD0.5 mg/kg IV over 40 minSSI, MADRS, HDRS, BDIScores on all scales were decreased significantly between 40 min and 4 hLarkin and Beautrais \[[@CR15]\]Open study, *n* = 14ED patients with SI0.2 mg/kg IV bolusMADRSScores decreased from 3.9 at baseline to 0.6 at 40 min; the effect lasted for 10 daysZarate et al. \[[@CR7]\]RCT crossover, *n* = 15Bipolar I or II disorder with current depressive episode0.5 mg/kg IV over 40 minMADRS-SI, HDRS, BDIMADRS: lower SI scores between 40 min and day 3\
HDRS: lower SI scores between 40--80 min and day 2\
BDI: lower SI scores between 40 min, day 2 and day 10Zigman and Blier \[[@CR14]\]Case reportTRD0.5 mg/kg IV over 40 minClinical interviewSI score decreased from 9/10 to 0/10; the effect lasted for 8 daysHarihar et al. \[[@CR13]\]Case reports, *n* = 2Depression0.5 mg/kg IVHDRSCase 1: HDRS score was decreased from 17 to 4 after 2 hCase 2: HDRS score was decreased from 21 to 6 after 2 hDe Gioannis and De Leo \[[@CR10]\]Case reports, *n* = 2TRD, previous suicide attempts0.5 mg/kg oral suspension titrated upMADRS-SICase 1: MADRS-SI score was decreased from 4/6 to 1/6 after 24 hCase 2: MADRS-SI score was decreased from 4/6 to 2/6 after 24 hPrice et al. \[[@CR11]\]Double-blind RCT, *n* = 57 (*n* = 36 for ketamine)TRD0.5 mg/kg IV over 40 min versus midazolam 0.045 mg/kgBSS, MADRS-SI, QIDS-SR, IATLower composite SI scores after 24 h with ketamine versus midazolam (*p* = 0.01)No difference in IAT score*BDI* Beck Depression Inventory, *BSS* Beck Scale for Suicide Ideation, *ED* emergency department, *HDRS* Hamilton Depression Rating Scale, *IAT* Implicit Association Test, *IV* intravenous(ly), *MADRS-SI* Montgomery--Åsberg Depression Rating Scale suicidal ideation item, *MDD* major depressive disorder, *QIDS-SR* Quick Inventory of Depressive Symptomatology---Self Report, *RCT* randomized controlled trial, *SSI* Scale for Suicide Ideation, *TRD* treatment-resistant depression

In the first study, by Berman et al. \[[@CR4]\], depressive symptoms, as assessed by the Hamilton Depression Rating Scale (HDRS), were measured before and after ketamine administration. As a secondary measure, an item-level analysis of the suicidality item on the HDRS was also performed. Although the specific scores on the suicidality item were not reported, the authors reported a statistically significant reduction (*p* = 0.02) between the baseline and final scores of suicidality.

Similarly, in their randomized controlled add-on trial, Zarate et al. \[[@CR7]\] examined SI as a secondary outcome, using the Montgomery--Åsberg Depression Scale (MADRS), HDRS, and Beck Depression Inventory (BDI) surveys. There were significant reductions in suicidality item scores in the 15 participants included in the study, beginning at 40 min and lasting for 3 days on the MADRS (*p* \< 0.001 for all three rating scales). The effects lasted for 2 days as assessed by the HDRS, and for up to 10 days as assessed by the BDI. After the ketamine infusion, there was a statistically significant improvement in suicidality on the suicide items of all three rating scales.

An open-label study by Price et al. in 2009 \[[@CR16]\] examined the effects of ketamine on SI, using the MADRS suicidal ideation item (MADRS-SI) and Implicit Association Test (IAT) measurements. Twenty-six patients with TRD were recruited. A subset of 13 of them had significant baseline SI (MADRS-SI score ≥4). These patients were administered ketamine 0.5 mg/kg intravenously over 40 min. Among the 13 patients, 8 (62 %) had an MADRS-SI score of ≤1 24 h postinfusion, 3 (23 %) had a score of 2--3, and two (15 %) remained at or above an MADRS-SI score of 4. The overall average reduction in MADRS-SI scores was just over 2 (*p* \< 0.001). It is interesting to report the results unique to that study related to implicit measures of suicidality. In a separate subset of 12 patients, implicit measures were assessed using the IAT, which assesses implicit suicidal associations and is a "behavioral measure of suicidal cognition." Statistical analysis revealed that stronger implicit associations correlated with higher MADRS-SI scores, and the implicit measurements significantly decreased after the ketamine infusion (*p* = 0.003).

In another open-label study, 33 patients with TRD currently experiencing a major depressive episode were given ketamine 0.5 mg/kg intravenously for specific observation of its effects on SI. SI was measured on four surveys: the Scale for Suicide Ideation (SSI), MADRS, HDRS, and BDI. The authors specifically used the SSI to determine the presence of baseline suicidality, and they found that 10 of the 33 patients had significant SSI scores of \>4. In this population, significant decreases in symptoms (SSI scores of \<4) were seen beginning at 40 min in nine of the patients and at 80 min in the tenth one. The average time to an SSI score of 0 for all 10 patients was 2 h. The improvement in their clinical symptoms lasted for up to 4 h. When the 33 patients were analyzed together, clinical improvement was seen across all four suicide scales from 40 to 230 min (*p* \< 0.001) \[[@CR17]\].

Larkin and Beautrais \[[@CR15]\] followed 14 patients who presented with SI to the emergency department (ED). The patients received an intravenous bolus of ketamine 0.2 mg/kg over 1--2 min. After the infusion, they were followed for 10 days and their symptoms were measured using the MADRS. These patients saw significant improvements in their clinical symptoms, beginning at 40 min, with the MADRS-SI score decreasing from 3.9 to 0.6. The patients subjectively reported relief of SI, which lasted for the 10 days that they were followed.

In their case report, Zigman and Blier \[[@CR14]\] described how a single infusion of ketamine 0.5 mg/kg over 40 min stabilized a patient with TRD and suicide intent with a plan. The patient had made a previous suicide attempt but had no other psychiatric history. She presented with an MADRS score of 48 and SI. She elected to receive ketamine rather than ECT. The patient reported immediate relief of her symptoms after the 40-min infusion. The patient reported that the effect of ketamine lasted for 8 days, and she denied any return of SI for the following month.

The second and third case reports, published by Harihar et al. \[[@CR13]\], followed two patients with depression and suicidality. The first patient had a psychiatric history of obsessive--compulsive disorder and worsening depression, including suicidal thoughts. He received ketamine 0.5 mg/kg intramuscularly after admission to the hospital for a suicide attempt. His HDRS score changed from a baseline of 17 to 4, 2 h after the ketamine treatment. The second patient had a history of recurrent major depression with recently worsening SI. After the same dose of ketamine, his HDRS score changed from 21 to 6. Neither patient reported any side effects.

The most recent case reports documented two patients with TRD, chronic SI, and multiple past suicide attempts. Both patients were given ketamine 0.5 mg/kg in a liquid suspension. For the first patient, his dose was titrated up to 3 mg/kg, where he attained a maximum response without side effects. His baseline MADRS-SI score was 4/6, and 24 h after the ketamine treatment, it had decreased to 1/6. The authors reported sustained remission with repeated oral dosing. However, no follow-up assessment was done. Similar results were seen in the second patient. The patient received a maximum dose of oral ketamine solution 1.5 mg/kg. She achieved a change in her MADRS-SI score from 4/6 to 2/6 after 24 h, and the authors also reported that she had sustained clinical remission of SI with monthly oral doses of ketamine \[[@CR10]\].

The largest study to date included 57 patients with TRD in a randomized double-blind placebo-controlled trial \[[@CR11]\]. Patients were randomized to receive either ketamine 0.5 mg/kg intravenously over 40 min or midazolam 0.045 mg/kg intravenously. Patients who were thought to be at imminent suicide risk were excluded from the study because of ethical considerations about using a placebo. A total of 36 patients received ketamine, and 21 received midazolam. As in the previous study conducted by this group, the patients were assessed for explicit and implicit suicidality. A combination of the Beck Scale for Suicide Ideation (BSS), MADRS-SI, and the Quick Inventory of Depressive Symptomatology-Self Report (QIDS-SR) comprised the explicit measurements in a measurement termed "SI composite scores," while the IAT looked at implicit associations. Results were compared 24 h after treatment. The ketamine treatment group experienced a greater reduction in SI composite scores than the placebo group (*p* = 0.01). In addition, 53 % of the treatment group scored 0 on explicit measures of suicide after 24 h, while only 24 % of the placebo group scored 0 (*p* = 0.03). When looking at implicit measures, the authors found no difference in the effect on implicit suicidality, based on the treatment after 24 h. They did note that the scores for one item on the IAT, "escape = me," decreased from baseline only in the ketamine group \[[@CR11]\].

Discussion {#Sec4}
==========

With an estimated prevalence of mood disorders ranging from 3.3 to 21.4 % and the substantially increased risk of suicide among patients with mood disorders, treatment is certainly warranted \[[@CR19]\]. Current treatment options for suicidality are limited. They include brain stimulation therapeutics, such as ECT, and pharmacological intervention (lithium, clozapine). The efficacy of lithium in treating suicidality has been documented \[[@CR20], [@CR21]\] and has recently been reviewed and pooled in a recent meta-analysis of 48 studies \[[@CR22]\]. Clozapine has also been shown to reduce suicide risk in patients with schizophrenia \[[@CR23], [@CR24]\]. The limitations of both lithium and clozapine include a longer time to efficacy in this psychiatric emergency/urgency, compared with the early response to ketamine \[[@CR25]\]. Ketamine seems to be gaining substantial evidence as a pharmacological option for depression with a fast onset of action, but its long-term effects need further investigation. In addition, ketamine probably offers a faster onset of action in terms of SI, but further work is certainly needed in this area. Given the risk of suicide and even the increasing rates of suicide in certain subgroups, such as soldiers and veterans \[[@CR26], [@CR27]\], there is an urgent need for faster therapeutics for SI and TRD. Importantly, suicidality and suicide pose a high global burden of patient suffering to families and society. Although several small-to-moderate sized studies, in addition to several reviews, have been published that have examined the efficacy of ketamine in TRD, there are considerably fewer published data specifically examining ketamine in patients presenting with SI. Notably, only three studies have directly examined SI as the primary outcome \[[@CR11], [@CR16], [@CR17]\], while the rest examined SI as the secondary outcome \[[@CR4], [@CR15], [@CR18]\], not including case reports. This review summarizes the current published literature regarding ketamine as a treatment for SI. The data so far show promising trends of ketamine being an effective and rapid treatment with minimal side effects.

Pharmacologically, ketamine is an *N*-methyl-[d]{.smallcaps}-aspartate (NMDA) receptor antagonist. It has been used for anesthesia in the USA since the 1970s. At subanesthetic doses, ketamine has been shown to increase glutamate levels \[[@CR3]\]. This mechanism is relevant, as glutamate regulation and expression are altered in patients with major depressive disorder (MDD). Studies have also demonstrated an abnormal glutamate--glutamine--gamma-aminobutyric acid cycle in patients with suicidality \[[@CR28]\]. Furthermore, ketamine has also been shown to work on nicotinic and opioid receptors \[[@CR29]\]. No other class of antidepressant medication works to modulate the glutamatergic system, and research continues into this, with the goal of characterizing the full mechanism of action of ketamine and perhaps developing other compounds that would have similar effects. Thus, even if the approval and marketing of ketamine as a rapid-acting antisuicidal and antidepressant medication is not realized, it could well be a prototype for development of other medication(s) that retain the mechanism of action with more favorable qualities and a lesser adverse effect profile (such as a longer duration of action or less or no addictive potential). Although the mechanisms explaining the antisuicidal effect and the NMDA receptor antagonism of ketamine are still unclear, some of the initial evidence points to an anti-inflammatory action via the kynurenic acid pathway. Strong suggestions as to the causal relationship between inflammation and depression/suicidality has come from studies demonstrating that cytokines \[[@CR30], [@CR31]\] and interferon-β \[[@CR32]\] induce depression and suicidality. Other recent studies have added to the notion of implicating brain immune activation in the pathogenesis of suicidality. For instance, one study showed microglial activation of postmortem brain tissue in suicide victims \[[@CR33]\]. Another study found increased levels of the cytokine interleukin-6 in cerebrospinal fluid from patients who had attempted suicide \[[@CR34]\]. Higher levels of inflammatory markers have been shown in suicidal patients than in non-suicidal depressed patients \[[@CR33], [@CR35]\]. Inflammation leads to production of both quinolinic acid (an NMDA agonist) and kynurenic acid (a NMDA antagonist). An increased quinolinic acid to kynurenic acid ratio leads to NMDA receptor stimulation. The correlation between quinolinic acid and Suicide Intent Scale scores indicates that changes in glutamatergic neurotransmission could be specifically linked to suicidality \[[@CR36]\].

Small randomized controlled trials have demonstrated the efficacy of ketamine in rapidly treating patients with both TRD and/or bipolar depression \[[@CR4], [@CR8], [@CR9], [@CR11], [@CR16]--[@CR18]\]. Some studies have also examined suicide items as a secondary measure in their depression rating scales \[[@CR4], [@CR7]\]. In total, the studies examining ketamine and TRD have nearly consistently demonstrated that ketamine provides relief from depressive and suicidal symptoms, starting at 40 min and lasting for as long as 5 days. Questions still remain as to the long-term effects of this treatment, how much should be administered and how often, any serious adverse effects, and the mechanism of action.

Pharmacologically, ketamine has poor bioavailability and is best administered via injection \[[@CR37]\]. In their landmark study, Berman et al. \[[@CR4]\] found that a subanesthetic dose (0.5 mg/kg) rapidly improved depressive symptoms. Most of the subsequent studies have delivered ketamine as a constant infusion for 40 min at a rate of 0.5 mg/kg. Others have examined its efficacy after multiple infusions and observed similar results \[[@CR8], [@CR13], [@CR16], [@CR38]\]. Currently, it is recommended that ketamine be administered in a hospital setting \[[@CR39]\].

Ketamine is considered to be a safe compound; however, it is not without its side effects. Some studies have reported symptoms of dissociation and hallucinations, although these are usually transient \[[@CR7], [@CR14], [@CR18]\]. A recent study of ketamine administration in 10 patients with obsessive--compulsive disorder reported an increase in anxiety and suicidal thoughts in two patients \[[@CR40]\]. Notably, these patients had extensive psychiatric comorbidity, and these findings have not been duplicated. Another potential concern is the long-term effects of ketamine. Studies regarding outcomes associated with long-term ketamine use are sparse. The current literature refers to patients who have abused ketamine as a recreational drug. In this population, the long-term consequences have not been described, but it is clear that further studies are needed in this area \[[@CR3]\].

The weaknesses of this review include possible bias in the way in which studies were selected for inclusion---including publication and selection bias. The literature is limited on this topic, as we have noted in this review. However, this review includes recent data from several randomized controlled trials, including one recent double-blind placebo-controlled trial. These trials were conducted by different groups and demonstrated similar findings. It must also be noted that differences in patient populations were not explored among the papers cited in this review. Some aspects of the efficacy of ketamine may be dependent on patient age, race, gender, etc., as evidenced by the differences in effect sizes noted among the studies, even when they used the same dosages and the same measurement tools. Larger studies with greater numbers of patients are needed to assess this further.

There are still several questions that need to be answered if standard clinical use of ketamine as an agent for treatment of SI is to be definitively pursued. Further studies are needed to better identify the best dose and delivery method of ketamine. Studies should specifically be conducted to assess SI as the primary, not secondary, outcome. Studies are also needed to further characterize the long-term benefits (if any) and the long-term risks/adverse effects, especially the abuse potential \[[@CR41]\]. Also, there are no data on prevention of suicide attempts or death by suicide. More information is also warranted to gain a better understanding of the mechanism of action of ketamine. This information could provide guidance for further drug development, as well as further insight into the pathogenesis of suicidality. Additionally, the exploration of compounds that function similarly to ketamine warrants attention. One of these compounds may be scopolamine, an antagonist at cholinergic muscarinic receptor sites. Studies have demonstrated effective resolution of depressive symptoms within 3 days of treatment with scopolamine in some patients \[[@CR42]\]. Also, the metabolite norketamine, which may be a possible player in the antidepressant and/or antisuicidal effect of ketamine \[[@CR43], [@CR44]\], deserves further research. Investigations into ketamine and other promising agents for emergent treatment of suicidality merit further research and replication in larger studies, in addition to further understanding of the mechanism of action. It should be noted that although NMDA antagonism has been proposed as the primary mechanism of action, some researchers have questioned that and raised the possibility that its stimulant action or opiate agonism might be more important than is currently appreciated \[[@CR41]\].

Conclusion {#Sec5}
==========

There is early preliminary evidence not only for the antidepressant action but also for the rapid antisuicidal action of ketamine. Further research is needed to achieve better understanding of the mechanism of action and the most appropriate route of administration, to better define dosing, and to examine the long-term adverse effects (including abuse potential) and benefits of ketamine, while exploring potential similar medications that might provide better side effect profiles, or that are more easily administered, in larger double-blind randomized clinical trials.
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